Trials / Completed
CompletedNCT01777555
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Acorda Therapeutics · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an outpatient (i.e., at home) and in the clinic.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CVT-301 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2013-01-29
- Last updated
- 2018-08-08
Locations
22 sites across 4 countries: United States, Italy, Serbia, United Kingdom
Source: ClinicalTrials.gov record NCT01777555. Inclusion in this directory is not an endorsement.